Tag Archives: NHS

Pursuing the 'Real' Cost Effectiveness Threshold in England

By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , , , , , | Leave a comment

UK Drug Pricing: An ICER of Zero?

by Leela Barham The incremental cost effectiveness ratio (ICER) – or the threshold for determining whether the costs of a new medicine are worth it – has been controversial since it’s inception. There are those who deny that anyone can put a price-tag on life; those that accept the concept but are happy to let […]
Posted in Europe, Guest Blog, healthcare, Legal, Market Access, pricing, Regulatory, Strategy | Also tagged , , , , | Leave a comment

England: Is the Cancer Drugs Fund Running Out of Money?

By Leela Barham. The headlines have moved on for the English Cancer Drugs Fund (CDF). Replacing the positive press releases such as “thousands of patients to benefit” in 2013 are headlines shouting out that “thousands face being denied life-extending medication”.  In other words, a return to the same concerns that prompted the creation of the […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Also tagged , , , | 1 Comment

Bid to Improve Access to Medicines in Scotland

Access to new medicines: A new, improved, approach in Scotland By Leela Barham A major Inquiry into access to new medicines across Scotland by the Scottish Health and Sport Committee has come to an end. The Scottish Government has responded, and announced changes to how Scotland makes decisions on what new medicines to use across […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed | Also tagged , , | Leave a comment

England's Latest Innovation Scorecard: A Patchy Picture

By Leela Barham. A common gripe from those in the pharma industry in England is that even when their products have been found to be cost effective by the National Institute for Health and Care Excellence (NICE) (not always easy to do these days), uptake in the NHS can be ‘low and slow’.  The latest […]
Posted in Europe, Global, Guest Blog, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta